Basel, Switzerland · Founded 2017 · Privately Held (backing)
Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. Nuclidium is based in Basel, Switzerland and was founded in 2017. Its last reported valuation was $163 million in Jul 2025. It has raised $101 million.
Last reported valuation
$163.2M
Oct 2026
Priced at
—
Total raised
$100.6M
Last round
—
Team — not yet on record
No current team members for Nuclidium are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Nuclidium with a free account
·The complete investor list: 13 names
·Watch Nuclidium: the Monday email on marks, rounds and moves
